News for Gilead Sciences, Inc. (GIS.DE)

**media[561032]**

Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.

In the current session, the stock is trading at $116.29, after a 0.22% spike. Over the past month, Gilead Sciences Inc. GILD stock increased by 21.08%, and in t...

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ETCompany ParticipantsJohanna Mercier - Chief...

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( NRIX), a clinical-stage biopharmaceutical company focused on the discovery, devel

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

”“ Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 ”“ ”“ Biomarker of

Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc. (GILD) and Medtronic plc (MDT), as well as two micro-cap stocks Cooper-Standard Holdings Inc. (CPS) and Rave Restaurant Group, Inc. (RAVE).

Gilead Sciences Inc (GILD) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) and EU-M4all applicati

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company's Marke

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc.

On February 18, 2025, Andrew Dickinson, the Chief Financial Officer of Kite Pharma, a subsidiary of Gilead Sciences Inc (GILD), sold 2,500 shares of the company

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.

On February 18, 2025, Gilead Sciences, Inc. executed a significant stock transaction involving Arcus Biosciences Inc (RCUS). The firm added 9,630,525 shares of

Gilead Sciences Inc (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar, a treatment for primary biliar

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions f

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.